1Dolhofer-Bliesener R,Lechner B,Deppisch R,et al.Immunological determination of advanced glycosylation end-products in human blood and urine.Nephrol Dial Transplant,1995,10(5):657-664.
2Miyata T,Ueda Y,Shinzato T,et al.Accumulation of albumin-linking and free-form pentosidine in the circulation of uremic patients with end-stage renal failure:Renal implications in the pathophysiology of pentosidine.J Am Soc Nephrol,1996,7(8):1198-1206.
4Miyata T,van Ypersele de Strihou C,Kurokawa K,et al.Alterations in nonenzymatic biochemistry in uremia:origin and significance of "carbonyl stress" in long-term uremic complications.Kidney Int,1999,55 (2):389-399.
5Schinzel R,Münch G,Heidland A,et al.Advanced glycation end products in end-stage renal disease and their removal.Nephron,2001,87(4):295-303.
6Miyata T,Wada Y,Cai Z,et al.Implication of increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure.Kidney Int,1997,51(4):1170-1181.
7Miyata T,Kurokawa K,van Ypersele de Strihou C.Advanced glycation and lipoxidation end products:role of reactive carbonyl compounds generated during carbohydrate and lipid metabolism.J Am Soc Nephrol,2000,11 (9):1744 -1752.
8Peter A.Evaluation and treatment of coronary artery disease in patients with end-stage renal disease.Kidney Int,2005,67(Suppl 95):51-58.
9Amann K,Ritz C,Adamczak M,et al.Why is coronary heart disease of uraemic patients so frequent and so devastating?Nephrol Dial Transplant,2003,18 (4):631-640.
10Kaneda H,Taguchi J,Ogasawara K,et al.Increased level of advanced oxidation protein products in patients with coronary artery disease.Atherosclerosis,2002,162 (1):221-225.
2Bobryshev YV, Lord RS. Mapping of vascular dendritic cells in atherosclerotic arteries suggests their involvement in local immune-inflammatory reactions. Cardiovasc Res, 1998, 37: 799-810.
3Kume S, Takeya M, Mori T, et al. Immunohistochemical and ultrastructural detection of advanced glycation end products in atherosclerotic lesions of human aorta with a novel specific monoclonal antibody.Am J Pathol, 1995, 147: 654-667.
4Cipollone F, Iezzi A, Fazia M, et al. The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control.Circulation, 2003, 108: 1070-1077.
5Wick G, Perschinka H, Millonig G. Atherosclerosis as an autoimmune disease: an update.Trends Immunol, 2001, 22: 665-669.
6Aicher A, Heeschen C, Mohaupt M, et al. Nicotine strongly activates dendritic cell-mediated adaptive immunity: potential role for progression of atherosclerotic lesions. Circulation, 2003, 107: 604-611.
7Alderman CJ, Bunyard PR, Chain BM, et al. Effects of oxidised low density lipoprotein on dendritic cells: a possible immunoregulatory component of the atherogenic micro-environment? Cardiovasc Res, 2002, 55: 806-819.
8Zhang L, Zalewski A, Liu Y, et al. Diabetes-induced oxidative stress and low-grade inflammation in porcine coronary arteries. Circulation, 2003, 108: 472-478.
9Kamada N, Kodama T, Suzuki H. Macrophage scavenger receptor (SR-A I/II) deficiency reduced diet-induced atherosclerosis in C57BL/6J mice. J Atheroscler Thromb, 2001, 8: 1-6.
10Hansen B, Svistounov D, Olsen R, et al. Advanced glycation end products impair the scavenger function of rat hepatic sinusoidal endothelial cells. Diabetologia, 2002, 45: 1379-1388.
